| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 08-14-2025 | 06-30-2025 | 10-Q | |
| 2 | 05-15-2025 | 03-31-2025 | 10-Q | |
| 3 | 03-31-2025 | 12-31-2024 | 10-K | |
| 4 | 11-14-2024 | 09-30-2024 | 10-Q | |
| 5 | 08-12-2024 | 06-30-2024 | 10-Q |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Alpha Cognition (NASDAQ:ACOG) with a Buy and lowers the price t...
Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" or the "Company"), a commercial-stage biopharmaceutical c...
Alpha Cognition Inc. (NASDAQ:ACOG), a commercial-stage biopharmaceutical company developing therapies for neurodegenerative dis...
Offering was led by an initial investment from a premier healthcare-dedicated investor alongside multiple large existing shareh...
Alpha Cognition Inc. (NASDAQ:ACOG) (the "Company"), a commercial-stage biopharmaceutical company dedicated to developin...
- SEC Filing
Alpha Cognition (NASDAQ:ACOG) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0...
